Daré Bioscience (DARE) Q3 2026 earnings review

Daré Bioscience delays its cream launch, while share count jumps

Daré Bioscience, a biotech firm developing women's health products, missed its third-quarter shipping target for its compounded sildenafil cream while initial probiotic sales barely registered. Total revenue was just $48,000, mostly from foundation research services, while commercial launch preparations pushed cost of revenues to $180,000. Chief executive Sabrina Martucci Johnson said the first sildenafil cream shipment is now on its way to the pharmacy for dispensing later in November.

At a glance
Total revenue$47.6K down 75% from last quarter
Cash and cash equivalents$11.5M $12.6M last quarter
Weighted average shares17.4M +17% from last quarter
Sildenafil cream revenue startPushed to Q4 previously expected in Q3

⚖️ Verdict: 🔴 Bearish

The story got worse because commercial launches keep slipping while share dilution accelerates to keep the company afloat. Average shares jumped 17% in a single quarter to restore working capital, yet management still expects product revenue to be immaterial for the full year. One bright spot: the company collected $2.4 million in fresh grant payments after the quarter closed to keep its clinical trials moving.

The question now is whether prescriptions written across 48 states will turn into paying customers and repeat refills once the pharmacy begins shipping this month. Bulls see early doctor interest as proof of pent-up demand, while bears note that management has never shared the total prescription count and expects tiny 2026 sales. Fourth-quarter product revenue in the annual report will settle it.

🐂 Bull Case

🟢 strengthening PRODUCT

Doctors Wrote Prescriptions Across 48 States Before Launch

Daré Bioscience wants to build a commercial business around DARE to PLAY, an unapproved compounded sildenafil cream for female sexual arousal made by a partner facility. Chief executive Sabrina Martucci Johnson said that "with product now on route to Medvantx, we expect prescription dispensing to commence later this month" across 28 states.

Before shipping a single tube, the women's health company convinced 182 office-based doctors to write prescriptions for the cream. Including online telehealth clinics, doctors have written prescriptions across 48 states and Washington, D.C. For its vaginal probiotic Flora Sync LF5, the firm also recorded orders from 27 states and its first repeat order from a doctor's office.

What to watch: fourth-quarter product revenue and the number of dispensed prescriptions in the full-year report. Those figures will show whether doctor interest turns into paying customers who refill their orders.

🟢 strengthening CASH

New Grant Installments Added $2.4 Million After Quarter End

"Non-dilutive funding is central to how we develop our pipeline," Johnson said, referring to government and foundation grants that pay for clinical trials without issuing new shares. After the third quarter closed, the biotech group collected $2.4 million in fresh grant payments by our math, plus an earlier $0.9 million federal award in August for a preterm birth program.

The company received $1.5 million in October for DARE-LARC1, its long-acting contraceptive implant, bringing total receipts to $43.3 million out of a potential $49.0 million award. In November, the Gates Foundation paid $0.9 million toward the Phase 3 trial of Ovaprene, a hormone-free monthly contraceptive ring. That leaves one final tranche of about $0.8 million by our math under that $10.7 million grant.

What to watch: the timing of the remaining $5.7 million in potential DARE-LARC1 grant funding. Because the Ovaprene grant is nearly used up, future trial offsets depend on new awards or hitting implant milestones.

🐻 Bear Case

🔴🔴 persistent GROWTH contradicts narrative

Sildenafil Cream Missed Its Target and Sales Stayed Tiny

Johnson said "the early response to Flora Sync LF5 is encouraging" after launching the vaginal probiotic in June and recording the first sales in July. However, total third-quarter revenue across the entire business was just $47,628, down 75% from last quarter by our math, and most of that came from research services for the Gates Foundation rather than product sales.

  • Total third-quarter revenue: $47,628, including both grant services and initial probiotic sales
  • Cost of revenues: $180,479, mostly for medical education around the sildenafil cream
  • Sildenafil cream revenue start: pushed from the third quarter to the fourth quarter of 2026

The sildenafil cream delay continues a pattern of missed commercial dates after management previously targeted a third-quarter revenue start. Even with shipments starting in November, Daré stated that it "does not expect the amount of such product revenue to be material during 2026". That means commercial sales will not cover the company's operating expenses this year.

What to watch: fourth-quarter product sales separated from grant service revenue in the annual filing. A tiny product number after November dispensing begins would show that initial prescriptions are not converting into meaningful cash flow.

🔴🔴 persistent CAPITAL ALLOCATION

Share Count Jumped 17% in One Quarter to Shore Up Capital

Because grant funds are restricted to specific research projects, the San Diego company must issue stock to pay for its general overhead and commercial launches. In the third quarter, weighted average diluted shares rose 17.0% from the second quarter and 36.6% from a year ago by our math, reaching 17.4 million shares.

That heavy share issuance helped lift working capital from a $0.2 million deficit in June to a positive $3.2 million, while stockholders' equity swung from negative $0.6 million to positive $2.3 million. However, raising money remains difficult because administrative expenses again included "a non-cash write-down of previously deferred offering costs", signaling that existing financing lines are yielding less cash than planned.

What to watch: exact share issuance proceeds and any new financing agreements in the third-quarter Form 10-Q filing. Even after the recent dilution, stockholders' equity of $2.34 million sits just below the standard $2.5 million threshold required to maintain a Nasdaq listing.

🔴 persistent MARGIN

Grant Offsets Shrank and Mask the True Research Spend

Daré records government and foundation grant money as contra-research and development (contra-R&D) expenses, which directly subtract from its reported research bill on the income statement. Reported research and development spending fell 72.9% from a year ago to $0.3 million, which helped narrow the quarterly net loss by 11.4% to $3.2 million.

Before those grant credits, total research spending was $5.0 million by our math, down from $6.2 million a year earlier as work wound down on older trials. The grant offsets themselves dipped 6.0% from a year ago to $4.7 million, marking the first year-over-year decline after rising in earlier quarters. When grant offsets shrink, reported losses can rise even if actual lab work stays steady.

What to watch: the deferred grant funding liability balance in the quarterly filing's footnotes. That figure shows how much unspent grant cash remains in the bank to offset future research bills.

🔴 persistent DISCLOSURE

Risks this quarter didn't answer

The third-quarter earnings release omitted updates on five standing financial, regulatory, and clinical concerns that require the full Form 10-Q filing or call transcript to check.

  • Unrestricted cash balance: how much of the $11.5 million cash pile is free to fund commercial operations rather than locked in grant accounts.
  • Nasdaq listing status: the outcome of the late-August hearing panel regarding the company's equity deficit and minimum bid price.
  • Ovaprene enrollment and FDA stance: whether the trial will finish enrolling 450 to 500 women this year and address prior FDA safety-size warnings.
  • Sildenafil Cream Phase 3 path: whether management reached agreement with the FDA on trial design or found a partner to fund the $15 million studies.
  • Royalty debt overhangs: any changes to the synthetic royalty and catch-up payment obligations owed to financing partners.

👓 Other Themes

new PRODUCT

Drug Delivery Chip Pitched for Obesity Partnerships

Daré is seeking partners for DARE-IDDS, the programmable drug-release technology inside its contraceptive implant, for chronic conditions such as obesity, diabetes, and "potential applications with GLP-1 medicines". In consumer health, the company plans to put Flora Sync LF5 on Amazon in early 2027 alongside two new vaginal care products, Flora Renew and Flora Reset.

💲 Other KPIs

Cash and cash equivalents (26Q3) $11.5 million
⇘ decelerating

Cash fell 8.6% from $12.6 million in the second quarter and is down 53.3% from $24.7 million at the end of 2025 by our math. In prior quarters, virtually the entire cash balance consisted of restricted grant funds earmarked for specific clinical trials rather than general corporate overhead.

Selling, general and administrative expenses (26Q3) $2.6 million
⇗ accelerating

Overhead and commercial spending rose 5.6% from a year ago and 1.8% from the second quarter by our math. Higher commercial-readiness costs, employee stock compensation, and a write-down of deferred financing costs drove the increase, partly offset by lower legal and general overhead bills.

Net loss per share (26Q3) -$0.18
⇘ decelerating

The net loss narrowed 11.4% from a year ago to $3.2 million, compared with $3.0 million in both the first and second quarters of 2026. Loss per share shrank 35.7% from -$0.28 a year ago by our math, largely because a 36.6% jump in the share count spread the loss across more shares.

🔮 Guidance

FY26 Product Revenue Materiality Not expected to be material
🠆 unchanged from Not expected to be material
⇒ stable

Unchanged. Management still expects combined 2026 sales from Flora Sync LF5 and DARE to PLAY Sildenafil Cream to be immaterial. Third-quarter revenue across all sources was $47,628, leaving the company reliant on grant installments and stock sales to fund operations through year-end.

DARE to PLAY Sildenafil Cream Revenue Start Q4 2026 (dispensing in November 2026)
🠇 cut from Q3 2026
⇘ decelerating

Cut. The company pushed initial revenue recognition from the third quarter to the fourth quarter of 2026, with pharmacy dispensing now slated for late November across 28 states. It is the fourth consecutive timeline slip since management originally targeted initial prescription fulfillment in December 2025.

DARE to RECLAIM Revenue Start 2027
🠆 unchanged from 2027
⇒ stable

Unchanged. Daré still targets 2027 to begin prescription dispensing and revenue for its compounded monthly estradiol and progesterone ring under Section 503B, while continuing preparatory work for a traditional FDA clinical trial application.

Ovaprene Phase 3 and DARE-HPV Phase 2 Topline Data 2027
🠆 unchanged from 2027
⇒ stable

Unchanged. The company continues to expect topline clinical trial results in 2027 for both its pivotal Phase 3 study of the Ovaprene contraceptive ring and its 100-patient Phase 2 study of the DARE-HPV vaginal insert.

❓ Key Questions

How many sildenafil cream prescriptions have doctors actually written?

Management reported that 182 office-based doctors and telehealth providers across 48 states have written prescriptions since February, but has never disclosed the total prescription count or how many expired waiting for November fulfillment.

How much of the $11.5 million cash is unrestricted?

At the end of June, the company's entire $12.6 million cash balance was restricted to grant-funded research projects. Investors need to know how much unrestricted cash sits on the balance sheet after the third-quarter share issuances.

What did the Nasdaq listing panel decide?

Stockholders' equity recovered to $2.34 million from a deficit in June, but remains slightly below the standard $2.5 million Nasdaq requirement. The press release did not disclose the status of the late-August delisting hearing.

How much revenue did Flora Sync LF5 generate in Q3?

Total revenue was $47,628, which management attributed primarily to Gates Foundation research services alongside the first quarter of Flora Sync LF5 sales. A breakdown would show actual consumer demand before the planned Amazon launch.